12. October 2022

OPPENLÄNDER advises Rieker Finanz-Gruppe

OPPENLÄNDER Rechtsanwälte advised Rieker Investment GmbH on the acquisition of a stake in KOBRA Formen GmbH.

KOBRA Formen GmbH was founded more than 30 years ago by Rudolf Braungardt and has since developed into the world’s leading mold maker. With around 500 employees worldwide – around 400 of them at the main site in Germany – and 6 subsidiaries in Europe and North America as well as sales partners in Canada, Europe and Asia, KOBRA Formen GmbH is a technological trendsetter in the concrete block market. The managing partner Holger Stichel will continue to lead the company together with the existing management. All internal company structures will remain in place in the same way. For an orderly company succession and for the strategic development of the group of companies, a strong partner, Rieker Investment GmbH, joins KOBRA Formen GmbH. As part of the Rieker Investment family, KOBRA Formen GmbH is positioned for the long term for the next decades and can continue its corporate strategy in the same way.

Rieker Investment GmbH is a company of the Rieker Finanz-Gruppe. The Rieker Finanz-Gruppe is an independent part of the Rieker Group, which also includes the shoe manufacturer Rieker Schuh. The Rieker Finanz-Gruppe invests in the long term and openly in medium-sized companies. The investments are managed independently by the existing management.

OPPENLÄNDER Rechtsanwälte provided comprehensive legal advice to the Rieker Finanz-Gruppe during the transaction. Various teams of international law firms in the respective countries, coordinated by OPPENLÄNDER, advised on the aspects of foreign law in Europe and North America. Under the leadership of Dr. Felix Born (Partner), the following OPPENLÄNDER team was active: Dr. Malte Weitner (Partner, IP/IT/Commercial), Dr. Christian Gunßer (Partner, Corporate/Finance), Dr. Damian Schmidt (Corporate/M&A), Dr. Anne-Kathrin Bichweiler (Corporate/M&A), Dr. Matthias Tratt (Corporate/M&A), Dr. Clemens Birkert (IT/Data Protection), Sven Luckert (Corporate/M&A/Labor Law) and Dr. Jens Ritter (Public Law/Subsidies).

The management of Rieker Finanz Group, Thomas Guhl and Axel Wiehrer, implemented the transaction in-house.

Click here for the JUVE report.

Dr. Felix Born

+49 (0)711 60187-232
born@oppenlaender.de

Dr. Malte Weitner

+49 (0)711 60187-176
weitner@oppenlaender.de

Dr. Christian Gunßer

+49 (0)711 60187-162
gunsser@oppenlaender.de

Dr. Anne-Kathrin Bichweiler

+49 (0)711 60187-250
bichweiler@oppenlaender.de

Dr. Matthias Tratt

+49 (0)711 60187-266
matthias.tratt@oppenlaender.de

Dr. Clemens Birkert

+49 (0)711 60187-204
clemens.birkert@oppenlaender.de

Sven Luckert

+49 (0)711 60187-154
sven.luckert@oppenlaender.de

More news

All news

27. November 2025

OPPENLÄNDER appoints two new partners

The OPPENLÄNDER partnership is growing. On January 1, 2026, Dr. Henrike Schulte will become a partner and Dr. Joachim Ott a salary partner at OPPENLÄNDER Rechtsanwälte. Both were previously associate partners at the firm.

21. November 2025

OPPENLÄNDER wins record damages for idealo

idealo has achieved a significant victory against Google in the Berlin Regional Court. The court confirmed that Google abused its market power far beyond the date of the Commission's decision in order to favor its own price comparison service and ordered the US corporation to pay damages of over €465 million, including interest.

31. October 2025

OPPENLÄNDER again receives JUVE TOP 50 Commercial Law Firm (Wirtschaftskanzlei) Award

"To the point: The strengths of this Stuttgart-based firm are not only in competition law and litigation – Oppenländer also enjoys an excellent reputation for advising in regulated industries." (JUVE quote)

13. October 2025

No compensation for isolation without possible vaccination – OPPENLÄNDER Rechtsanwälte wins for the state of Baden-Württemberg

On October 9, 2025, the Federal Administrative Court ruled that an employed person who was in quarantine in October 2021 due to infection with the coronavirus and thus suffered a loss of earnings cannot claim compensation from the state under the Infection Protection Act if they did not take advantage of the vaccination publicly recommended at the time despite having sufficient opportunity to do so. Translated with DeepL.com (free version)